Since mid-2002, two new antifungal drugs — voriconazole, a third-generation azole, and caspofungin, a member of a new class of drugs called echinocandins — have been marketed in Spain.

Background Voriconazole is approved for treatment of invasive aspergillosis and other invasive fungal infections, but the role for therapeutic drug monitoring (TDM) is not clear. Methods We ...